Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Metoprolol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 known ✓ | P08588 | 4/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 3/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | CYP2J2 | P51589 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
| ▸ | NPY1R | P25929 | 1/20 | 0.84 |
| ▸ | NPY2R | P49146 | 1/20 | 0.84 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.84 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.84 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.84 |
| ▸ | LMNA | P02545 | 2/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
| ▸ | GAA | P10253 | 1/20 | 0.67 |
| ▸ | BLM | P54132 | 1/20 | 0.67 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (S)-Metoprolol SCHEMBL121589 | 1.00 | ADRB1 (1.00) | ADRB1ADRB2CYP2D6NR3C1ADRA1A | |
| Metoprolol SCHEMBL1561123 | 1.00 | ADRB1 (1.00) | ADRB1ADRB2CYP2D6NR3C1ADRA1A | |
| (R)-Metoprolol SCHEMBL40918 | 1.00 | ADRB1 (1.00) | ADRB1ADRB2CYP2D6NR3C1ADRA1A | |
| Metoprolol SCHEMBL28445291 | 0.99 | ADRB1 (0.97) | ADRB1ADRB2CYP2D6NR3C1ADRA1A | |
| (S)-Metoprolol SCHEMBL2638035 | 0.99 | ADRB1 (0.97) | ADRB1ADRB2CYP2D6NR3C1ADRA1A | |
| Metoprolol SCHEMBL6126034 | 0.99 | ADRB1 (0.97) | ADRB1ADRB2CYP2D6NR3C1ADRA1A | |
| (S)-Metoprolol SCHEMBL6728301 | 0.99 | ADRB1 (0.97) | ADRB1ADRB2CYP2D6NR3C1ADRA1A | |
| Metoprolol SCHEMBL2638034 | 0.99 | ADRB1 (0.97) | ADRB1ADRB2CYP2D6NR3C1ADRA1A | |
| Metoprolol SCHEMBL27911917 | 0.99 | ADRB1 (0.97) | ADRB1ADRB2CYP2D6NR3C1ADRA1A | |
| Metoprolol SCHEMBL613509 | 0.99 | ADRB1 (0.97) | ADRB1ADRB2CYP2D6NR3C1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 49196 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| EP-4744654-A1 | SIGMA-1 RECEPTOR AGONIST SYSTOLIC BLOOD PRESSURE THERAPY | Anavex Life Sciences Corp. (US) | 2026-05-20 | — | — | EP | claimed |
| US-20260120206-A1 | HOME ENERGY MANAGEMENT SYSTEM AND BIDIRECTIONAL REAL-TIMEPRICE PREDICTION METHOD FOR DEMAND RESPONSE | UNIV CHUNG ANG IND ACAD COOP FOUND (KR) | 2026-04-30 | — | — | US | claimed |
| WO-2026087695-A1 | TREATMENT FOR METABOLIC DISORDER | SAPREME TECHNOLOGIES B.V. (NL) | 2026-04-30 | — | — | WO | claimed |
| WO-2026090164-A1 | COMPOSITIONS COMPRISING ELISMETREP AND A SECOND THERAPEUTIC AGENT FOR TREATING OR PREVENTING MIGRAINE OR PAIN | KALLYOPE, INC. (US) | 2026-04-30 | — | — | WO | claimed |
| WO-2026087680-A1 | TREATMENT FOR CARDIOVASCULAR DISEASE | SAPREME TECHNOLOGIES B.V. (NL) | 2026-04-30 | — | — | WO | claimed |
| EP-4731194-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING AN ACTIVE AGENT | CSP Technologies, Inc. (US) | 2026-04-29 | — | — | EP | claimed |
| EP-4732835-A1 | THIOACRYLAMIDE DERIVATIVE FOR USE IN THE PREVENTION OR TREATMENT OF OBESITY | CMR CureDiab Metabolic Research GmbH (DE) | 2026-04-29 | — | — | EP | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| EP-4727545-A2 | COMBINATION TREATMENTS FOR DEPRESSION AND OTHER DISORDERS | Neurawell Therapeutics (US) | 2026-04-22 | — | — | EP | claimed |
| US-4327725-A | Osmotic device with hydrogel driving member | ALZA CORPORATION (US) | 1982-05-04 | — | — | US | claimed |
| EP-0041760-A1 | Process for the preparation of 1-isopropylamino-3-(4-(2-methoxy-ethyl)-phenoxy)-2-propanol | Aktiebolaget Hässle (SE) | 1981-12-16 | — | — | EP | claimed |
| EP-0041295-A1 | Process for the preparation of 1-isopropylamino-3-(4-(2-methoxy-ethyl)-phenoxy)-2-propanol | Aktiebolaget Hässle (SE) | 1981-12-09 | — | — | EP | claimed |
| US-4303637-A | Medication indicated for ocular hypertension | ALZA CORPORATION (US) | 1981-12-01 | — | — | US | claimed |
| EP-0037622-A2 | Drug delivery insert for controlled ocular therapy | ALZA CORPORATION (US) | 1981-10-14 | — | — | EP | claimed |
| EP-0036138-A2 | Composition of matter for topical application comprising a bio-affecting agent and N,N-diethyl-m-toluamide | MERCK & CO. INC. (US) | 1981-09-23 | — | — | EP | claimed |
| US-4281654-A | Drug delivery system for controlled ocular therapy | ALZA CORPORATION (US) | 1981-08-04 | — | — | US | claimed |
| US-4256108-A | Microporous-semipermeable laminated osmotic system | ALZA CORPORATION (US) | 1981-03-17 | — | — | US | claimed |
| US-4161530-A | CYCLIC SUBSTITUTED AMINO ALCOHOL BETA-RECEPTOR-BLOCKING AGENT AND TRYPTOPHANE | CIBA-GEIGY CORPORATION (US) | 1979-07-17 | — | — | US | claimed |
| US-4139633-A | ISOPROPYLAMINOPROPANE DERIVATIVES, SUBSTITUTED BENZENE SULPHONAMIDE | CIBA-GEIGY CORPORATION (US) | 1979-02-13 | — | — | US | claimed |